Neuroprotection by cannabidiol and hypothermia in a piglet model of newborn hypoxic-ischemic brain damage

Barata, Lorena; Arruza, Luis; Rodríguez, M. Cabello; Aleo, Esther; Vierge, Eva; Sobrino, Elena; Vargas, Carlos; Ceprián, María; Gutiérrez-Rodríguez, Ana; Hind, William; Martı́nez-Orgado, José

doi:10.1016/j.neuropharm.2018.11.020

Cited by 42 publications

(48 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The peak plasma concentrations were also similar to those reported for day old piglets after 1.0 mg/kg CBD, i.v. (Barata et al, 2019) but higher than those reported in humans (~62 ng/mL) using a plant material vaporizer with 11%THC/11%CBD cannabis (Arkell et al, 2019).…”

Section: Discussionmentioning

confidence: 62%

Vapor inhalation of cannabidiol (CBD) in rats

Javadi‐Paydar

Creehan²,

Kerr

et al. 2019

Preprint

View full text Add to dashboard Cite

Cannabidiol (CBD), a compound found in many strains of the Cannabis genus, is increasingly available in e-cigarette liquids as well as other products. CBD use has been promoted for numerous purported benefits which have not been rigorously assessed in preclinical studies. To further validate an inhalation model to assess CBD effects in the rat. The primary goal was to determine plasma CBD levels after vapor inhalation and compare that with the levels observed after injection. Secondary goals were to determine if hypothermia is produced in male Sprague-Dawley rats and if CBD affects nociception measured by the warm water tail-withdrawal assay. Blood samples were collected from rats exposed for 30 minutes to vapor generated by an e-cigarette device using CBD (100, 400 mg/mL in the propylene glycol vehicle). Separate experiments assessed the body temperature response to CBD in combination with nicotine (30 mg/mL) and the anti-nociceptive response to CBD. Vapor inhalation of CBD produced concentration-related plasma CBD levels in male and female Wistar rats that were within the range of levels produced by 10 or 30 mg/kg, CBD, i.p.. Dose-related hypothermia was produced by CBD in male Sprague-Dawley rats, and nicotine (30 mg/mL) inhalation enhanced this effect. CBD inhalation had no effect on anti-nociception alone or in combination with Δ 9tetrahydrocannabinol inhalation. The vapor-inhalation approach is a suitable pre-clinical model for the investigation of the effects of inhaled CBD. This route of administration produces hypothermia in rats, while i.p. injection does not, at comparable plasma CBD levels.

show abstract

Section: Discussionmentioning

confidence: 62%

Vapor inhalation of cannabidiol (CBD) in rats

Javadi‐Paydar

Creehan²,

Kerr

et al. 2019

Preprint

View full text Add to dashboard Cite

show abstract

“…Other preclinical studies have investigated the impact of CBD on different animal models of acute neuronal injury, in particular, acute cerebral HI [4,13,31,68,69,80,81,83,100,105,127,129,142,143,153]. Studies administering a single (acute) dose of CBD shortly post-HI (e.g.…”

Section: Neuroprotection-concussion and Subconcussionmentioning

confidence: 99%

Cannabidiol and Sports Performance: a Narrative Review of Relevant Evidence and Recommendations for Future Research

et al. 2020

View full text Add to dashboard Cite

Cannabidiol (CBD) is a non-intoxicating cannabinoid derived from Cannabis sativa. CBD initially drew scientific interest due to its anticonvulsant properties but increasing evidence of other therapeutic effects has attracted the attention of additional clinical and non-clinical populations, including athletes. Unlike the intoxicating cannabinoid, Δ 9-tetrahydrocannabinol (Δ 9-THC), CBD is no longer prohibited by the World Anti-Doping Agency and appears to be safe and well-tolerated in humans. It has also become readily available in many countries with the introduction of over-the-counter "nutraceutical" products. The aim of this narrative review was to explore various physiological and psychological effects of CBD that may be relevant to the sport and/ or exercise context and to identify key areas for future research. As direct studies of CBD and sports performance are is currently lacking, evidence for this narrative review was sourced from preclinical studies and a limited number of clinical trials in non-athlete populations. Preclinical studies have observed robust anti-inflammatory, neuroprotective and analgesic effects of CBD in animal models. Preliminary preclinical evidence also suggests that CBD may protect against gastrointestinal damage associated with inflammation and promote healing of traumatic skeletal injuries. However, further research is required to confirm these observations. Early stage clinical studies suggest that CBD may be anxiolytic in "stress-inducing" situations and in individuals with anxiety disorders. While some case reports indicate that CBD improves sleep, robust evidence is currently lacking. Cognitive function and thermoregulation appear to be unaffected by CBD while effects on food intake, metabolic function, cardiovascular function, and infection require further study. CBD may exert a number of physiological, biochemical, and psychological effects with the potential to benefit athletes. However, well controlled, studies in athlete populations are required before definitive conclusions can be reached regarding the utility of CBD in supporting athletic performance.

show abstract

“…61,86,87 CBD also enhances membrane fluidity, 88 increases 2-AG levels, 89 and upregulates CB 1 receptor expression. 90 Several studies have demonstrated the neuroprotective properties of the CBD in different conditions, such as newborn hypoxic-ischemic encephalopathy, 79 chronic cerebral hypoperfusion, 91 neonatal iron overload, 92 and kainic acid-induced seizures. 93 The neuroprotective properties of CBD do not appear to depend on direct activation of CB 1 receptors, 94 but can be related to a reduction in glutamate excitotoxicity and oxidative stress, 79 neuroinflammation decrease, 91 anti-apoptotic action, 92 or modulation/polarization of glial cells.…”

Section: Cannabidiol and Neuroprotectionmentioning

confidence: 99%

“…90 Several studies have demonstrated the neuroprotective properties of the CBD in different conditions, such as newborn hypoxic-ischemic encephalopathy, 79 chronic cerebral hypoperfusion, 91 neonatal iron overload, 92 and kainic acid-induced seizures. 93 The neuroprotective properties of CBD do not appear to depend on direct activation of CB 1 receptors, 94 but can be related to a reduction in glutamate excitotoxicity and oxidative stress, 79 neuroinflammation decrease, 91 anti-apoptotic action, 92 or modulation/polarization of glial cells. 93 In spite of the involvement of CB 2 receptors in the neuroprotective effect of CBD in a model of hypoxicischemic in newborn mice, 79 the possibility of its direct action at these receptors remains controversial.…”

Section: Cannabidiol and Neuroprotectionmentioning

confidence: 99%

“…93 The neuroprotective properties of CBD do not appear to depend on direct activation of CB 1 receptors, 94 but can be related to a reduction in glutamate excitotoxicity and oxidative stress, 79 neuroinflammation decrease, 91 anti-apoptotic action, 92 or modulation/polarization of glial cells. 93 In spite of the involvement of CB 2 receptors in the neuroprotective effect of CBD in a model of hypoxicischemic in newborn mice, 79 the possibility of its direct action at these receptors remains controversial. 86,87 CBD also interacts with several other targets.…”

Section: Cannabidiol and Neuroprotectionmentioning

confidence: 99%

See 1 more Smart Citation

Biological bases for a possible effect of cannabidiol in Parkinson’s disease

Ferreira‐Junior

Campos

Guimarães

et al. 2020

Braz. J. Psychiatry

View full text Add to dashboard Cite

Current pharmacotherapy of Parkinson's disease (PD) is palliative and unable to modify the progression of neurodegeneration. Treatments that can improve patients' quality of life with fewer side effects are needed, but not yet available. Cannabidiol (CBD), the major non-psychotomimetic constituent of cannabis, has received considerable research attention in the last decade. In this context, we aimed to critically review the literature on potential therapeutic effects of CBD in PD and discuss clinical and preclinical evidence supporting the putative neuroprotective mechanisms of CBD. We searched MEDLINE (via PubMed) for indexed articles published in English from inception to 2019. The following keywords were used: cannabis; cannabidiol and neuroprotection; endocannabinoids and basal ganglia; Parkinson's animal models; Parkinson's history; Parkinson's and cannabidiol. Few studies addressed the biological bases for the purported effects of CBD on PD. Six preclinical studies showed neuroprotective effects, while three targeted the antidyskinetic effects of CBD. Three human studies have tested CBD in patients with PD: an open-label study, a case series, and a randomized controlled trial. These studies reported therapeutic effects of CBD on non-motor symptoms. Additional research is needed to elucidate the potential effectiveness of CBD in PD and the underlying mechanisms involved.

show abstract

Neuroprotection by cannabidiol and hypothermia in a piglet model of newborn hypoxic-ischemic brain damage

Cited by 42 publications

References 24 publications

Vapor inhalation of cannabidiol (CBD) in rats

Vapor inhalation of cannabidiol (CBD) in rats

Cannabidiol and Sports Performance: a Narrative Review of Relevant Evidence and Recommendations for Future Research

Biological bases for a possible effect of cannabidiol in Parkinson’s disease

Contact Info

Product

Resources

About